Cytotoxicity in Epstein Barr virus specific immune control

Christian Münz

Research output: Contribution to journalReview articlepeer-review

19 Scopus citations

Abstract

Epstein Barr virus (EBV) is the most common human tumor virus, persistently infecting more than 95% of the human adult population and readily transforming human B cell in culture. Fortunately, only a small minority of EBV carriers develops virus associated malignancies. The majority controls persistent EBV infection with cytotoxic lymphocytes, mainly NK, γδ and CD8+ T cells and the characteristics of the required immune responses get more and more defined by primary immunodeficiencies that affect molecules of these cytotoxic lymphocytes and their investigation in mice with reconstituted human immune system components (humanized mice) that are susceptible to EBV infection and associated lymphomagenesis. The gained information should be able to guide us to develop immunotherapies against EBV and tumors in general.

Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalCurrent Opinion in Virology
Volume46
DOIs
StatePublished - Feb 2021
Externally publishedYes

Fingerprint

Dive into the research topics of 'Cytotoxicity in Epstein Barr virus specific immune control'. Together they form a unique fingerprint.

Cite this